EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Engineering oncolytic bacteria as precision cancer therapeutics: design principles, therapeutic strategies, and translational perspectives

Lingxue Niu iD, Zhenqiang Deng iD, Yiyu Jin iD, Ningzi Guan iD, Haifeng Ye iD

Protein & Cell · 01.04.2026 · 17 (4) · 279-303

DOI: 10.1093/procel/pwaf085 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Protein & Cell, online erschienen am 23.10.2025. Verfasst von Lingxue Niu und 4 weiteren Autor:innen. Beteiligte Einrichtung: Shanghai Frontiers Science Center of Genome Editing and Cell Therapy, Biomedical Synthetic Biology Research Center, Shanghai Key Laboratory of Regula…. Hauptthemen laut MEDLINE: Neoplasms, Precision Medicine, Bacteria, Genetic Engineering. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 191 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Noncommunicable Chronic Diseases, National Science and Technology Major Project, National Key R&D Program of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Engineered oncolytic bacteria are emerging as a promising platform for precision cancer therapy, combining inherent tumor tropism, immunogenicity, and programmable gene control. Advances in synthetic biology now enable inducible and autonomous circuits that sense exogenous inputs (chemical signals or physical signals), bacterial self-cues (quorum sensing, bacterial invasion switches, or nitric oxide-responsive promoters), and tumor-specific pathophysiology (hypoxia, low pH, or lactate). These designs regulate colonization, lysis, and the spatiotemporally confined release of therapeutic cargos—including prodrug-converting enzymes, cytokines, and antibody/nanobody fragments—thereby enhancing antitumor efficacy while limiting off-target toxicity. Beyond monotherapy, oncolytic bacteria integrate with complementary modalities—including immune checkpoint blockade, adoptive cell therapies (CAR-T/NK), radiotherapy/chemotherapy, nanomedicine, and oncolytic viruses—to amplify immune activation and to enable multimodal, synergistic regimens. Concurrently, biosensor modules transform bacterial chassis into programmable “microbial factories” that couple therapy with real-time imaging and adaptive responses within the tumor microenvironment. This review synthesizes design principles for bacterial gene regulation, surveys recent preclinical advances, and highlights emerging combination strategies, while outlining translational considerations for safety, manufacturability, dosing, and patient selection. Together, these developments position engineered oncolytic bacteria as a promising route toward safe, effective, and ultimately personalized bacteria-based cancer therapeutics.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NeoplasmsPrecision MedicineBacteriaGenetic EngineeringHumansAnimalsTranslational Research, BiomedicalOncolytic Viruses

Stichwörter der Autor:innen

gene circuitsoncolytic bacteriaprecision cancer therapysynthetic biology

Autor:innen und Institutionen

  • Shanghai Frontiers Science Center of Genome Editing and Cell Therapy, Biomedical Synthetic Biology Research Center, Shanghai Key Laboratory of Regulatory Biology, Institute of Biomedical Sciences and School of Life Scie…
  • Shanghai SynBioEra Biotechnology Co., Ltd., Shanghai 200241, China.

ORCID-Profile: Lingxue Niu, Zhenqiang Deng, Yiyu Jin, Ningzi Guan, Haifeng Ye

Förderung

  • Noncommunicable Chronic Diseases
  • National Science and Technology Major Project
  • National Key R&D Program of China
  • National Natural Science Foundation of China
  • Science and Technology Commission of Shanghai Municipality
  • Natural Science Foundation of Shanghai
  • SANS Exploration Scholar

Zitieren

APA

Niu, L., Deng, Z., Jin, Y., Guan, N., & Ye, H. (2026). Engineering oncolytic bacteria as precision cancer therapeutics: design principles, therapeutic strategies, and translational perspectives. Protein & Cell, 17(4), 279-303. https://doi.org/10.1093/procel/pwaf085

Vancouver

Niu L, Deng Z, Jin Y, Guan N, Ye H. Engineering oncolytic bacteria as precision cancer therapeutics: design principles, therapeutic strategies, and translational perspectives. Protein & Cell. 2026;17(4):279-303. doi:10.1093/procel/pwaf085

BibTeX
@article{Niu2026,
  author = {Niu, Lingxue and Deng, Zhenqiang and Jin, Yiyu and Guan, Ningzi and Ye, Haifeng},
  title = {Engineering oncolytic bacteria as precision cancer therapeutics: design principles, therapeutic strategies, and translational perspectives},
  journal = {Protein & Cell},
  year = {2026},
  volume = {17},
  number = {4},
  pages = {279--303},
  doi = {10.1093/procel/pwaf085}
}
Kostenlos starten →